Menin is also critical in regulating genes that drive cancer growth in acute myeloid leukemia (AML), and more recently, targeting menin’s interaction with KMT2A has emerged as a promising therapeutic strategy for treating AML, especially with KMT2A rearrangement and NPM1 mutations. This evidence concerns the gene NPM1 and acute myeloid leukemia.